To see whether Grp94 was the tumor antigen shared by any patient irrespective of the anatomical site and stage of the tumor, we performed histo-immunochemistry (IHC) analysis on any sample of tumor tissue (and its normal counterpart), and measured Grp94 in patients’ plasma. This evidence concerns the gene HSP90B1 and neoplasm.